Trial Profile
A Phase 1, Open Label, Non-Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Oral Seladelpar in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects With Normal Hepatic Function
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Jan 2020
Price :
$35
*
At a glance
- Drugs Seladelpar (Primary)
- Indications Liver dysfunction
- Focus Pharmacokinetics
- Sponsors CymaBay Therapeutics
- 17 May 2018 Status changed from recruiting to completed.
- 02 Apr 2018 Planned End Date changed from 1 Mar 2018 to 1 Apr 2018.
- 02 Apr 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Apr 2018.